Attenuation of Dupuytren’s fibrosis via targeting of the STAT1 modulated IL-13Rα1 response

PU.1 controls fibroblast polarization and tissue fibrosis

(2019) Thomas Wohlfahrt et al.   NATURE

Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis

(2019) David Izadi et al.   Science Advances

α-smooth muscle actin is not a marker of fibrogenic cell activity in skeletal muscle fibrosis

(2018) Wanming Zhao et al.   PLoS One

IL11 is a crucial determinant of cardiovascular fibrosis

(2017) Sebastian Schafer et al.   NATURE

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

The emerging safety profile of JAK inhibitors in rheumatic disease

(2017) Kevin L. Winthrop   Nature Reviews Rheumatology

Effect of Compound 21, a Selective Angiotensin II Type 2 Receptor Agonist, in a Murine Xenograft Model of Dupuytren Disease

(2017) Jessica Chisholm et al.   PLASTIC AND RECONSTRUCTIVE SURGERY

Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis

(2017) Kelly L. Walton et al.   Frontiers in Pharmacology

Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-γ

(2016) Thirumalai R Ramalingam et al.   JOURNAL OF PATHOLOGY

TGF-β: the master regulator of fibrosis

(2016) Xiao-ming Meng et al.   Nature Reviews Nephrology

Tenascin-C drives persistence of organ fibrosis

(2016) Swati Bhattacharyya et al.   Nature Communications

Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD

(2016) Noam Jacob et al.   United European Gastroenterology Journal

Developing an animal model of Dupuytren’s disease by orthotopic transplantation of human fibroblasts into athymic rat

(2015) Latha Satish et al.   BMC MUSCULOSKELETAL DISORDERS

Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy?

(2015) Enrica Bianchi et al.   CLINICAL SCIENCE

JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis

(2015) J. Yan et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

A protective role for IL-13 receptor α 1 in bleomycin-induced pulmonary injury and repair

(2015) D Karo-Atar et al.   Mucosal Immunology

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

(2014) D L Boyle et al.   ANNALS OF THE RHEUMATIC DISEASES

Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target

(2013) L. S. Verjee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxia: a critical regulator of early human tendinopathy

(2011) Neal L Millar et al.   ANNALS OF THE RHEUMATIC DISEASES

Reversal of TGF-β1 stimulation of α-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's - derived fibroblasts

(2011) Latha Satish et al.   BMC MUSCULOSKELETAL DISORDERS

Identification of an IFN-γ/mast cell axis in a mouse model of chronic asthma

(2011) Mang Yu et al.   JOURNAL OF CLINICAL INVESTIGATION

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

Wnt Signaling and Dupuytren's Disease

(2011) Guido H. Dolmans et al.   NEW ENGLAND JOURNAL OF MEDICINE

Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors

(2011) Mark J. Anderton et al.   TOXICOLOGIC PATHOLOGY

IL-33 Induces IL-13-Dependent Cutaneous Fibrosis

(2009) A. L. Rankin et al.   JOURNAL OF IMMUNOLOGY

Transforming growth factor β as a therapeutic target in systemic sclerosis

(2009) John Varga et al.   Nature Reviews Rheumatology